VSMAX
Price
$140.61
Change
+$1.15 (+0.82%)
Updated
Sep 11 closing price
Net Assets
185.27B
WICVX
Price
$10.09
Change
-$0.03 (-0.30%)
Updated
Sep 11 closing price
Net Assets
1.27B
Interact to see
Advertisement

VSMAX vs WICVX

VSMAX vs WICVX Comparison Chart in %
View a ticker or compare two or three
VS
VSMAX vs. WICVX commentary
Sep 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is VSMAX is a Hold and WICVX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VSMAX has more cash in the bank: 185B vs. WICVX (1.27B). VSMAX pays higher dividends than WICVX: VSMAX (1.20) vs WICVX (0.09). VSMAX was incepted earlier than WICVX: VSMAX (26 years) vs WICVX (15 years). WICVX (1.06) is less costly to investors than VSMAX (0.05). WICVX is a more actively managed with annual turnover of: 65.00 vs. VSMAX (17.00). VSMAX has a lower initial minimum investment than WICVX: VSMAX (3000) vs WICVX (100000). VSMAX annual gain was more profitable for investors over the last year : 14.06 vs. WICVX (-1.27). VSMAX return over 5 years is better than : 34.02 vs. WICVX (-7.15).
VSMAXWICVXVSMAX / WICVX
Total Expense Ratio0.051.055%
Annual Report Gross Expense Ratio0.051.065%
Fund Existence26 years15 years-
Gain YTD13.96411.001127%
Front LoadN/AN/A-
Min. Initial Investment30001000003%
Min. Initial Investment IRAN/AN/A-
Net Assets185B1.27B14,613%
Annual Yield % from dividends1.200.091,309%
Returns for 1 year14.06-1.27-1,109%
Returns for 3 years50.936.93734%
Returns for 5 years34.02-7.15-476%
Returns for 10 years155.4157.75269%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TCIEX31.470.29
+0.93%
Nuveen International Eq Idx R6
SEEIX15.090.11
+0.73%
SEI International Equity I (SIT)
TRACX22.640.12
+0.53%
PGIM Quant Solutions Small-Cap Val C
LONAX16.520.07
+0.43%
Longboard A
FBTDX173.53-0.39
-0.22%
Franklin Biotechnology Discovery C